News | August 03, 2021
Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
Complementary business models are the reason for the acquisition
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
Subscribe To Our Newsletter & Stay Updated
